cTNM | ||||||
---|---|---|---|---|---|---|
IA | Higher | |||||
(85) | (209) | %IA | OR | 95% CI | ||
Patient characteristics and constitution | ||||||
Age at diagnosis | ||||||
Median | Median | |||||
72.0 | 69.9 | |||||
-59 | 10 | 29 | 25.6 | 0.60 | 0.27 | 1.35 |
60–69 | 26 | 76 | 25.5 | 0.59 | 0.33 | 1.07 |
70–79 | 42 | 73 | 36.5 | 1.00 | ||
≥ 80 | 7 | 31 | 18.4 | 0.39 | 0.16 | 0.97 |
Chi2(3) = 5.9; p = 0.11 | ||||||
Sex | ||||||
Male | 40 | 120 | 25.0 | 1.00 | ||
Female | 45 | 89 | 33.6 | 1.52 | 0.91 | 2.52 |
Chi2(1) = 2.6; p = 0.11 | ||||||
Charlson comorbidity score | ||||||
0 | 29 | 99 | 22.7 | 1.00 | ||
1 | 21 | 47 | 30.9 | 1.53 | 0.79 | 2.95 |
2 | 19 | 22 | 46.3 | 2.95 | 1.41 | 6.18 |
≥ 3 | 16 | 41 | 28.1 | 1.33 | 0.65 | 2.71 |
Chi2(3) = 8.3; p = 0.04 | ||||||
Pack-years | ||||||
≥ 40 | 32 | 99 | 24.4 | 1.00 | ||
20–39 | 33 | 76 | 30.3 | 1.34 | 0.76 | 2.38 |
10–19 | 9 | 14 | 39.1 | 1.99 | 0.79 | 5.03 |
0–9 | 10 | 8 | 55.6 | 3.87 | 1.41 | 10.63 |
NA | 1 | 12 | 7.7 | 0.26 | 0.03 | 2.06 |
Chi2(3) = 7.9; p = 0.048 (ex. NA) | ||||||
Morphology | ||||||
Small cell carcinoma | 2 | 29 | 6.5 | 0.12 | 0.03 | 0.52 |
Adenocarcinoma | 57 | 99 | 36.5 | 1.00 | ||
Squamous cell carcinoma | 9 | 39 | 18.8 | 0.40 | 0.18 | 0.89 |
NSCLC unspecified | 8 | 24 | 25.0 | 0.58 | 0.24 | 1.37 |
Other and NA | 9 | 18 | 33.3 | 0.87 | 0.37 | 2.06 |
Chi2(4) = 12.6; p = 0.01 | ||||||
Referral | ||||||
Initiation of referral | ||||||
General practice | 38 | 127 | 23.0 | 0.52 | 0.31 | 0.87 |
Hospital | 47 | 82 | 36.4 | 1.00 | ||
Chi2(1) = 6.2; p = 0.01 | ||||||
Red flag symptoms (PPV, %)* | ||||||
0.0 | 34 | 63 | 35.1 | 1.36 | 0.78 | 2.37 |
0.1–0.9 | 39 | 98 | 28.5 | 1.00 | ||
≥ 1 | 12 | 48 | 20.0 | 0.63 | 0.30 | 1.31 |
Chi2(2) = 4.0; p = 0.13 | ||||||
Diagnostics | ||||||
Initial imaging conclusion | ||||||
Suspicious for cancer | 40 | 176 | 18.5 | 1.00 | ||
Referral for follow-up | 36 | 24 | 60.0 | 6.60 | 3.55 | 12.27 |
Non-suspicious | 9 | 9 | 50.0 | 4.40 | 1.64 | 11.79 |
Chi2(2) = 38.9; p < 0.001 | ||||||
Index image | ||||||
CECT | 19 | 46 | 29.2 | 1.00 | ||
LDCT | 25 | 37 | 40.3 | 1.64 | 0.78 | 3.42 |
Xray | 23 | 87 | 20.9 | 0.64 | 0.32 | 1.30 |
None of the above | 18 | 39 | 31.6 | 1.12 | 0.52 | 2.42 |
Chi2(3) = 7.4; p = 0.06 | ||||||
Imaging cascade | ||||||
CECT direct | 16 | 42 | 27.6 | 1.00 | ||
LDCT or ULDCT | 22 | 40 | 35.5 | 1.44 | 0.66 | 3.14 |
Xray then CECT | 9 | 66 | 12.0 | 0.36 | 0.15 | 0.88 |
Xray then LDCT | 21 | 28 | 42.9 | 1.97 | 0.88 | 4.41 |
Other | 17 | 33 | 34.0 | 1.35 | 0.60 | 3.07 |
Chi2(4) = 15.5; p = 0.004 | ||||||
Clinical pathway | ||||||
Pathway | ||||||
Lung cancer referral pathway | 5 | 19 | 20.8 | 1.00 | ||
Urgent referral pathway for non-specific serious symptoms | 12 | 33 | 26.7 | 1.38 | 0.42 | 4.52 |
LDCT pathway | 25 | 37 | 40.3 | 2.57 | 0.85 | 7.78 |
Not a defined clinical pathway | 43 | 120 | 26.4 | 1.36 | 0.48 | 3.87 |
Chi2(3) = 5.2; p = 0.16 | ||||||
Timing of investigation and diagnosis | ||||||
Days from investigation to diagnosis | ||||||
Less than 31 | 42 | 180 | 18.9 | 1.00 | ||
31–60 | 8 | 11 | 42.1 | 3.12 | 1.18 | 8.23 |
61–179 | 12 | 8 | 60.0 | 6.43 | 2.47 | 16.72 |
≥ 180 | 23 | 10 | 69.7 | 9.86 | 4.36 | 22.27 |
Chi2(3) = 41.1; p < 0.001 |